• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.16% Nasdaq Down0.13%

    MacroGenics, Inc. (MGNX)

    32.23 Up 0.26(0.81%) 4:00PM EDT
    |After Hours : 32.23 0.00 (0.00%) 4:32PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    MacroGenics, Inc.
    9640 Medical Center Drive
    Rockville, MD 20850
    United States - Map
    Phone: 301-251-5172
    Fax: 301-251-5321
    Website: http://www.macrogenics.com

    Index Membership:N/A
    Full Time Employees:211

    Business Summary 

    MacroGenics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the company to generate product candidates and enter into various strategic collaborations with global pharmaceutical and biotechnology companies. Its product candidates include Margetuximab, a monoclonal antibody that targets human epidermal growth factor receptor 2-expressing tumors, including breast and gastroesophageal cancers; MGA271, an antibody for various solid tumor types; MGD006, a humanized dual-affinity re-targeting (DART) molecule for the treatment of patients with acute myeloid leukemia; and MGD007, a DART protein to treat colorectal cancer. The company’s products also comprise Teplizumab, an anti-CD3 monoclonal antibody for the treatment of Type 1 Diabetes; MGD011, a DART for treatment of various hematological malignancies; MGD009, a DART molecule for the recognition of undisclosed solid tumor; and MGD010, a DART-based molecule for autoimmune diseases. The company has strategic collaborations primarily with Les Laboratoires Servier and Institut de Recherches Servier; Gilead Sciences, Inc.; Boehringer Ingelheim International GmbH; Pfizer, Inc.; Eli Lilly & Co. and Green Cross Corp.; and Takeda Pharmaceutical Company Limited. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on MacroGenics, Inc.

    Corporate Governance 
    MacroGenics, Inc.’s ISS Governance QuickScore as of May 1, 2015 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 9; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Scott Koenig M.D., Ph.D., 63
    Chief Exec. Officer, Pres and Director
    Mr. James Karrels , 48
    Chief Financial Officer, Sr. VP and Corp. Sec.
    Dr. Ezio Bonvini M.D., 61
    Sr. VP of Research
    Mr. Atul Saran , 42
    Sr. VP and Gen. Counsel
    Mr. Joseph Panigot J.D.,
    VP of Legal Affairs
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders